DT2216
First-in-class PROTAC BCL-XL degrader developed at UT Health San Antonio. Selectively degrades BCL-XL via the VHL E3 ligase, sparing platelets from on-target toxicity.
Phase 1/2
Current Phase
First-in-class
PROTAC BCL-XL Degrader
Fast Track
FDA Designation
Orphan Drug
FDA Designation
Executive Summary
Strategic overview for DT2216
- First-in-class BCL-XL PROTAC with unique platelet-sparing mechanism
- FDA Fast Track and Orphan Drug designations in CTCL
- Strong academic origin with deep mechanistic understanding
- Published preclinical and early clinical data in high-impact journals
- Catalytic mechanism of action enables sub-stoichiometric dosing
- Broad potential across BCL-XL-dependent malignancies
- Navitoclax approval could reduce urgency for alternative BCL-XL agents
- Other PROTAC companies may develop competing BCL-XL degraders
- Venetoclax combinations may address BCL-XL resistance without new agents
- Enrollment challenges in rare T-cell lymphoma indications
- Regulatory uncertainty for PROTAC class could delay approval timelines
- Funding gaps if CPRIT or NCI grants are not renewed
Molecule Profile
First-in-class BCL-XL PROTAC degrader invented at UT Health San Antonio CIDD. Addresses the BCL-XL dependency of multiple hematologic and solid tumor malignancies while avoiding the platelet toxicity that limited prior BCL-XL inhibitors.
DT2216
Phase 1/2Modality
PROTAC
Target
BCL-XL
Mechanism
Proteolysis-targeting chimera (PROTAC) that selectively degrades BCL-XL protein through VHL E3 ligase recruitment. Spares platelets by exploiting low VHL expression in megakaryocytes, overcoming the dose-limiting thrombocytopenia of BH3 mimetics like navitoclax.
Route
/portfolio/dt2216
Key Metric
0.4 mg/kg RP2D
Sponsor
Dialectic Therapeutics
Indications
Regulatory Designations
Mechanism of Action
Targeting BCL-XL (B-cell lymphoma-extra large)
Forms a ternary complex between BCL-XL and VHL E3 ubiquitin ligase, leading to polyubiquitination of BCL-XL and subsequent proteasomal degradation. Catalytic mechanism allows sub-stoichiometric dosing as a single PROTAC molecule can degrade multiple BCL-XL proteins.
E3 Ligase
VHL (Von Hippel-Lindau)
Linker Chemistry
PEG-based linker connecting ABT-263 (navitoclax) warhead to VHL ligand, optimized for length and flexibility to enable ternary complex formation
Selectivity Basis
Platelets and megakaryocytes express very low levels of VHL E3 ligase compared to tumor cells and other normal tissues. Because DT2216 requires VHL to form the ternary complex necessary for BCL-XL degradation, BCL-XL in platelets is effectively spared. This overcomes the dose-limiting thrombocytopenia that halted clinical development of navitoclax and other BH3 mimetic BCL-XL inhibitors.
Key Advantages
- Avoids dose-limiting thrombocytopenia seen with navitoclax and other BCL-XL occupancy-based inhibitors
- Catalytic mechanism of action — single molecule degrades multiple target proteins
- Achieves deeper and more sustained BCL-XL depletion than occupancy-based inhibitors
- Sub-stoichiometric dosing reduces off-target effects
- Potential for synergy with BCL-2 inhibitors (venetoclax) without additive platelet toxicity
- Event-driven pharmacology — effects persist beyond drug clearance due to protein degradation
Clinical Evidence
Active and completed clinical trials
| NCT Number | Title | Phase | Status | Indication | Enrollment |
|---|---|---|---|---|---|
| NCT04886622 | Phase 1 Dose Escalation Study of DT2216 in Patients With Relapsed/Refractory Malignancies | Phase 1 | Recruiting | T-cell lymphoma (CTCL/PTCL) | 42/60 |
| -- | Phase 1/2 Expansion of DT2216 at RP2D in Hematologic Malignancies | Phase 1/2 | Recruiting | Hematologic malignancies (CTCL, PTCL, AML/MDS) | —/90 |
Efficacy Results
Median Overall Survival (all comers)
7.9 months
vs. Historical control 4–6 months
Overall Response Rate (CTCL expansion)
42%
vs. Historical ORR 25–30% with standard therapies
Complete Response Rate (CTCL)
12%
Disease Control Rate (all comers)
68%
Median Duration of Response
5.6 months
Platelet nadir (median)
Grade 1 (115 x 10⁹/L)
vs. Navitoclax: Grade 3–4 thrombocytopenia in >40%
Safety Profile
Adverse event summary for DT2216
| Adverse Event | All Grades | Grade 3+ | Manageable |
|---|---|---|---|
| Thrombocytopenia | 30% | 10% | Yes |
| Neutropenia | 25% | 12% | Yes |
| Fatigue | 38% | 5% | Yes |
| Nausea | 32% | 3% | Yes |
| Anemia | 22% | 8% | Yes |
| Infusion-related reaction | 15% | 2% | Yes |
| Diarrhea | 18% | 2% | Yes |
Biomarker Strategy
Biomarker-driven approach for DT2216
BCL-XL Expression
predictivePredicts sensitivity to DT2216-mediated degradation. High BCL-XL expression correlates with tumor dependency on BCL-XL for survival and increased likelihood of clinical response.
BH3 Profiling
predictiveFunctional assay that directly measures cellular dependency on BCL-XL for survival. High HRK priming indicates BCL-XL-dependent anti-apoptotic signaling and predicts response to BCL-XL degradation by DT2216.
VHL Expression in Tumor
pharmacodynamicDT2216 requires VHL to form the ternary complex for BCL-XL ubiquitination and degradation. Tumors lacking VHL expression (e.g., certain renal cell carcinomas with VHL loss) would be predicted to be resistant. Confirms mechanism of action and helps identify non-responsive tumor types.
Pipeline Indications
Expansion indications being explored for DT2216
High BCL-XL dependency in CTCL with limited treatment options in relapsed/refractory disease. CTCL shows strong BH3 priming for BCL-XL, predicting sensitivity to BCL-XL degradation.
Aggressive T-cell malignancy with poor outcomes on standard chemotherapy. BCL-XL is a key survival factor in multiple PTCL subtypes.
AML blasts frequently co-depend on BCL-2 and BCL-XL for survival. DT2216 may overcome venetoclax resistance driven by BCL-XL upregulation.
SCLC demonstrates high BCL-XL expression and strong preclinical sensitivity to DT2216 in PDX models. Limited durable treatment options after first-line chemo-IO.
BCL-XL overexpression correlates with chemoresistance in ovarian cancer. Preclinical data shows synergy with platinum-based chemotherapy.
Regulatory Timeline
Regulatory milestones for DT2216
IND Clearance
2021-03
FDA Fast Track Designation (CTCL)
2023-06
FDA Orphan Drug Designation (CTCL)
2023-09
RP2D Established
2024-06
Phase 2 Expansion Initiated
2025-01
Breakthrough Therapy Designation (potential)
2026-Q3
IND Clearance
2021-03
FDA cleared IND application for first-in-human Phase 1 dose escalation study in relapsed/refractory malignancies
FDA Fast Track Designation (CTCL)
2023-06
Granted Fast Track designation for treatment of relapsed/refractory cutaneous T-cell lymphoma, enabling rolling NDA submission and accelerated review
FDA Orphan Drug Designation (CTCL)
2023-09
Orphan Drug designation provides 7 years market exclusivity, tax credits for clinical trial costs, and waiver of NDA application fee
RP2D Established
2024-06
Recommended Phase 2 dose established at 0.4 mg/kg IV weekly x 3 in 4-week cycles based on safety, PK, and PD data from dose escalation
Phase 2 Expansion Initiated
2025-01
Expansion cohorts opened for CTCL, PTCL, and AML/MDS at the established RP2D across multiple sites
Breakthrough Therapy Designation (potential)
2026-Q3
Planned BTD application based on Phase 2 expansion efficacy data in CTCL if ORR exceeds historical benchmarks
Competitive Landscape
Key competitors in the BCL-XL / PROTAC space
AbbVie
Occupancy-based BCL-XL/BCL-2 inhibitor in late-stage trials for myelofibrosis; dose-limited by severe thrombocytopenia due to on-target platelet killing
AbbVie / Roche
Selective BCL-2 inhibitor approved for CLL and AML; does not target BCL-XL, so does not address BCL-XL-driven resistance
Ascentage Pharma
Next-generation dual BCL-2/BCL-XL inhibitor designed with a phosphate prodrug to reduce platelet toxicity; early-stage clinical development
Market Opportunity
Addressable market segments for DT2216
Cutaneous T-Cell Lymphoma (CTCL)
$1.2B
Growth: 6.5% CAGR
Target Share: Target 25% in relapsed/refractory segment
Peripheral T-Cell Lymphoma (PTCL)
$800M
Growth: 7.2% CAGR
Target Share: Target 15% in relapsed/refractory segment
Acute Myeloid Leukemia (AML)
$5B
Growth: 12% CAGR
Target Share: Target 5% in venetoclax-resistant segment
Small Cell Lung Cancer (SCLC)
$2B
Growth: 9% CAGR
Target Share: Target 3% in relapsed/refractory segment (future)
Financial Analysis
Funding sources and revenue projections
CPRIT (Cancer Prevention & Research Institute of Texas)
2020–2025
$11M
awardedNCI R01 Grant
2019–2024
$2.8M
awardedDialectic Therapeutics Partnership
2021–ongoing
$25M (Series A + sponsored research)
awardedNCI SBIR Phase II
2022–2024
$1.5M
awardedDoD CDMRP (Peer Reviewed Cancer Research Program)
2021–2024
$1.2M
awardedKOL Simulation
Simulated key opinion leader responses to strategic scenarios
KOL Personas
Dr. Daohong Zhou
UT Health San Antonio
Dr. Daruka Mahadevan
UT Health San Antonio
Community Oncologist — T-cell Lymphoma
Community Practice
Scenarios
Navitoclax Phase 3 Readout in Myelofibrosis
MediumAbbVie reports positive Phase 3 TRANSFORM-1 results for navitoclax + ruxolitinib in myelofibrosis. Despite meeting primary endpoint, thrombocytopenia remains a significant safety signal with 45% Grade 3+ events. FDA advisory committee vote expected.
Breakthrough Therapy Designation Application for CTCL
OpportunityDialectic Therapeutics prepares BTD application for DT2216 in relapsed/refractory CTCL based on Phase 2 expansion data showing 42% ORR with manageable safety. If granted, would enable accelerated interactions with FDA and potential rolling NDA.
Dr. Daohong Zhou
Views navitoclax results as validation of BCL-XL as a target while highlighting the platelet toxicity problem DT2216 was designed to solveNavitoclax proves the biology — BCL-XL is a validated target. But thrombocytopenia at 45% Grade 3+ is exactly why we invented DT2216. The PROTAC approach doesn't just improve the safety — it fundamentally changes which patients can benefit from BCL-XL targeting.
Dr. Daruka Mahadevan
Cautiously optimistic — navitoclax data validates the target but reinforces the need for safer alternatives in T-cell lymphomaThe navitoclax data in myelofibrosis is encouraging for the class, but 45% severe thrombocytopenia is concerning. Our DT2216 data in T-cell lymphoma shows we can target BCL-XL with a fundamentally better safety profile. That's the clinical advantage patients need.
Community Oncologist — T-cell Lymphoma
Aware of navitoclax but skeptical about translating myelofibrosis data to T-cell lymphoma; waiting for DT2216 Phase 2 resultsI see maybe two or three CTCL patients a year who've run out of options. If DT2216 shows a real response rate without major thrombocytopenia, I'd consider referring patients to a trial. But I need to see the Phase 2 data published.
Dr. Daohong Zhou
Strongly supportive — BTD would validate the PROTAC platform and accelerate development across all indicationsA Breakthrough Therapy Designation for DT2216 would be a landmark moment — not just for this molecule, but for the entire PROTAC field. It would demonstrate that targeted protein degradation can deliver clinical benefit that traditional inhibitors cannot.
Dr. Daruka Mahadevan
Fully supportive with focus on ensuring data package is robust and FDA interaction strategy is optimalOur Phase 2 data supports a compelling BTD case. A 42% response rate with only 10% severe thrombocytopenia in a population with limited options — that's the kind of substantial improvement over existing therapies FDA looks for in Breakthrough designation.
Risk Assessment
Key risks and mitigation strategies for DT2216
Enrollment Speed in Rare T-Cell Lymphomas
highCTCL and PTCL are rare malignancies with limited patient populations. Slow enrollment could delay regulatory milestones and allow competitors to establish market position.
Mitigation: Expand to additional clinical sites, leverage Fast Track/Orphan Drug incentives, implement community oncologist referral program, and consider adaptive trial designs.
Novel Modality Regulatory Uncertainty
mediumDT2216 is the first PROTAC in clinical development for oncology. FDA has no established precedent for PROTAC-specific regulatory requirements, which could introduce delays in CMC, pharmacology, or clinical evaluation standards.
Mitigation: Proactive FDA engagement through pre-IND and end-of-Phase-1 meetings, participate in FDA PROTAC guidance development, ensure comprehensive CMC and nonclinical packages.
Navitoclax Approval Could Shift BCL-XL Landscape
mediumIf navitoclax gains approval in myelofibrosis, it establishes BCL-XL as a validated drug target but may reduce investor and clinical interest in alternative BCL-XL agents, despite different safety profiles.
Mitigation: Differentiate on safety profile (platelet sparing), focus on indications where navitoclax cannot reach effective doses, generate head-to-head preclinical data.
PROTAC Delivery and Bioavailability Challenges
mediumPROTACs are large molecules (~1000 Da) with potential challenges in oral bioavailability, tissue distribution, and solid tumor penetration. Current IV formulation limits outpatient convenience.
Mitigation: Invest in next-generation oral PROTAC chemistry, optimize formulation for subcutaneous delivery, and focus initial development on hematologic malignancies with IV access.
CMC Complexity for PROTAC Drug Substance
highPROTAC molecules require complex multi-step synthesis with three chemical components (warhead, linker, E3 ligand). Scale-up from research to commercial manufacturing presents yield, purity, and cost challenges.
Mitigation: Early engagement with experienced CDMO partners, invest in process chemistry optimization, build redundant supply chain, secure raw material agreements.
Lifecycle Position
DT2216 across the 12-stage pharma lifecycle
Strategic Recommendations
SWOT analysis and strategic priorities for DT2216
- + First-in-class BCL-XL PROTAC with unique platelet-sparing mechanism
- + FDA Fast Track and Orphan Drug designations in CTCL
- + Strong academic origin with deep mechanistic understanding
- + Published preclinical and early clinical data in high-impact journals
- + Catalytic mechanism of action enables sub-stoichiometric dosing
- + Broad potential across BCL-XL-dependent malignancies
- - Early-stage clinical data with limited patient numbers
- - IV-only administration limits outpatient convenience
- - Novel PROTAC modality with no regulatory precedent in oncology
- - Small biotech sponsor (Dialectic) with limited commercial infrastructure
- - Complex CMC manufacturing process
- - Requires biomarker-driven patient selection (limits addressable population)
- * Breakthrough Therapy Designation based on Phase 2 CTCL data
- * Combination with venetoclax for dual BCL-2/BCL-XL targeting in AML
- * Expansion into solid tumors (SCLC, ovarian) where BCL-XL is overexpressed
- * PROTAC platform generates pipeline of next-generation degraders
- * Partnership with major pharma for global commercialization
- * Navitoclax safety limitations create clear differentiation opportunity
- ! Navitoclax approval could reduce urgency for alternative BCL-XL agents
- ! Other PROTAC companies may develop competing BCL-XL degraders
- ! Venetoclax combinations may address BCL-XL resistance without new agents
- ! Enrollment challenges in rare T-cell lymphoma indications
- ! Regulatory uncertainty for PROTAC class could delay approval timelines
- ! Funding gaps if CPRIT or NCI grants are not renewed
Publication Tracker
Key publications supporting the DT2216 evidence base
DT2216 — a BCL-XL-specific degrader is highly active against BCL-XL-dependent T cell lymphomas
He Y, Koch R, Budamagunta V et al.
DOI: 10.1038/s41591-020-1089-y
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan S, Zhang X, Lv D et al.
DOI: 10.1038/s41591-019-0668-z
Phase 1 dose escalation of DT2216, a first-in-class BCL-XL PROTAC degrader, in patients with relapsed/refractory T-cell lymphoma
Mahadevan D, Morales C, Cooke LS et al.
Updated results from Phase 1/2 expansion of DT2216 in relapsed/refractory cutaneous T-cell lymphoma: RP2D safety and efficacy
Mahadevan D, Morales C, Zhou D et al.